Celltrion/Pfizer Agree To Wait For Mid-September Inflectra Launch

Celltrion Inc. and Pfizer Inc., who have been waiting to launch their biosimilar Inflectra (infliximab-dyyb) pending an ongoing legal dispute, have agreed to wait a little bit longer – now until after Sept. 15 under a stipulation with Janssen Biotech Inc., whose monoclonal antibody Remicade was the innovator on which the copycat was referenced.

Under a stipulation, Korean firm Celltrion Inc. and its partner New York pharma mammoth Pfizer Inc. have agreed not to launch their biosimilar Inflectra (infliximab-dyyb) until after Sept. 15, absent certain conditions.

Janssen Biotech Inc., a subsidiary of Johnson & Johnson, whose drug Remicade (infliximab) was the reference on which...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip